Medication-Assisted Treatment (MAT) in Jacksonville, FL

Medication-assisted treatment (MAT) is the clinical practice of combining FDA-approved medications — buprenorphine, methadone, or naltrexone — with behavioral therapy and counseling to treat opioid and alcohol use disorders, producing outcomes significantly superior to either medication or therapy alone. MAT is not substituting one addiction for another; it is evidence-based medicine that normalizes brain chemistry, reduces cravings, and prevents the dangerous cycle of withdrawal and relapse. In Jacksonville, Duval County was awarded a CDC Overdose Data to Action (OD2A) grant specifically to expand overdose prevention and treatment capacity, reflecting the federal recognition that the region's opioid crisis — with a death rate of 52.1 per 100,000 — demanded expanded access to MAT and other evidence-based interventions through the Florida Department of Health in Duval County.

What are the three medications commonly used to treat opioid addiction?

The three FDA-approved medications for opioid addiction treatment are buprenorphine, methadone, and naltrexone. Each works through a distinct pharmacological mechanism. Buprenorphine is a partial opioid agonist — it activates opioid receptors enough to prevent withdrawal and reduce cravings but has a ceiling effect that limits euphoria and respiratory depression risk. Methadone is a full opioid agonist that provides steady-state opioid receptor activation at controlled doses, eliminating withdrawal and blocking the effects of other opioids. Naltrexone is an opioid antagonist that completely blocks opioid receptors, preventing any opioid from producing an effect. All three are listed on the World Health Organization's List of Essential Medicines and are endorsed by every major American medical organization as first-line treatment for opioid use disorder.

Mechanism comparison: agonist vs. antagonist

Partial agonist (buprenorphine): Partially activates opioid receptors. Produces mild opioid effect at low doses, then plateaus. Prevents withdrawal and reduces cravings. Ceiling effect makes overdose from buprenorphine alone extremely unlikely. Can be prescribed in office-based settings. Full agonist (methadone): Fully activates opioid receptors at controlled doses. Provides stronger withdrawal suppression than buprenorphine. Must be dispensed through licensed opioid treatment programs (OTPs). Overdose risk exists if diverted or combined with other depressants. Antagonist (naltrexone): Blocks opioid receptors completely. Prevents any opioid from producing an effect. Requires complete detox before initiation (7-14 days opioid-free). Available as daily pill or monthly injection (Vivitrol). No abuse potential.

What are examples of medication-assisted treatments for opioid addiction?

Medication-assisted treatments for opioid addiction include several formulations across the three approved medications. Buprenorphine formulations: Suboxone (buprenorphine/naloxone sublingual film), Subutex (buprenorphine sublingual tablet), Sublocade (monthly injectable buprenorphine), Zubsolv (buprenorphine/naloxone sublingual tablet), and Probuphine (buprenorphine implant providing 6 months of treatment). Methadone formulations: oral liquid or tablet dispensed daily at licensed clinics. Naltrexone formulations: ReVia (daily oral tablet) and Vivitrol (monthly intramuscular injection). In Jacksonville inpatient programs, the most common MAT protocol involves buprenorphine induction during detox with transition to either maintenance buprenorphine or injectable naltrexone before discharge, depending on clinical assessment and patient preference.

What is the new drug to treat opioid addiction?

The most significant recent pharmaceutical development for opioid addiction treatment is Sublocade (extended-release buprenorphine injectable), approved in 2017 and increasingly adopted as a standard-of-care option. Sublocade provides a monthly subcutaneous injection that delivers steady-state buprenorphine levels for 26-30 days, eliminating the need for daily sublingual dosing and removing adherence as a variable in treatment success. Clinical trials showed that Sublocade achieved 40% higher treatment retention compared to daily sublingual buprenorphine, primarily by eliminating daily dosing decisions. Lofexidine (Lucemyra), approved in 2018, is the first non-opioid medication specifically approved for managing opioid withdrawal symptoms — it reduces autonomic symptoms like sweating, anxiety, and elevated blood pressure without activating opioid receptors. While not a long-term treatment, it provides an alternative for patients who cannot tolerate opioid agonist therapy.

What medications are used to treat opioid addiction?

Beyond the three primary medications (buprenorphine, methadone, naltrexone), several adjunct medications are used in comprehensive opioid addiction treatment. Clonidine manages autonomic withdrawal symptoms including anxiety, sweating, and elevated blood pressure. Trazodone and hydroxyzine address the severe insomnia that accompanies opioid withdrawal and early recovery. Gabapentin may be used for anxiety and pain management during the post-acute withdrawal phase. Psychiatric medications — SSRIs, mood stabilizers — treat co-occurring depression or anxiety disorders that frequently accompany opioid use disorder. In Jacksonville inpatient programs, the medication protocol is individualized based on opioid type, duration of use, prior treatment history, co-occurring conditions, and patient preference.

What are the medicine choices in opioid substitution treatment?

Opioid substitution treatment — now more accurately called opioid agonist therapy — offers two medicine choices: buprenorphine and methadone. The choice between them depends on severity of dependence, treatment setting, and patient factors. Buprenorphine is appropriate for most people with opioid use disorder and can be prescribed in office-based settings, emergency departments, and inpatient programs. Its partial agonist mechanism provides a safety margin against overdose. Methadone is reserved for severe, long-duration opioid dependence and requires dispensing through licensed opioid treatment programs with daily observed dosing initially. Its full agonist mechanism provides stronger craving suppression but requires more intensive monitoring. Clinical guidelines recommend starting with buprenorphine for most patients, reserving methadone for those who do not achieve stabilization on buprenorphine or who have previously failed buprenorphine treatment.

Which medication is commonly used to prevent opioid withdrawal?

Buprenorphine is the most commonly used medication to prevent opioid withdrawal during detoxification and maintenance treatment. When administered at appropriate doses (8-24mg daily for sublingual formulations), buprenorphine occupies opioid receptors sufficiently to prevent withdrawal symptoms from developing. For people transitioning from fentanyl, micro-dosing induction protocols — where very small buprenorphine doses (0.5-1mg) are gradually increased over 3-7 days while fentanyl is still partially present — have become the preferred approach in Jacksonville inpatient programs because they avoid the precipitated withdrawal that occurs with traditional buprenorphine induction. Once stabilized, buprenorphine can be continued indefinitely as maintenance treatment, with clinical guidelines recommending at least 12 months of continuous medication before considering a gradual taper.

What medication is used for opioid addiction?

The three FDA-approved medications for opioid addiction are buprenorphine (brand names Suboxone, Sublocade, Subutex), methadone, and naltrexone (brand names Vivitrol, ReVia). Among these, buprenorphine is the most widely prescribed in the United States, used by approximately 1.5 million people. Methadone is used by approximately 400,000 people through licensed opioid treatment programs. Naltrexone is used by approximately 100,000 people, primarily in the injectable Vivitrol formulation. The choice of medication is not one-size-fits-all — it depends on the individual's severity of dependence, prior treatment response, co-occurring conditions, lifestyle factors, and personal preference. All three are considered first-line treatments, and no clinical evidence supports one as universally superior to the others.

Related Resources